Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM201 combinations in AML and high-risk MDS
NCT03940352Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jun 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of siremadlin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Novartis. Primary endpoints: Adverse Events at 24 months, Serious Adverse Events at 24 months and 4 more. Started Jun 2019; status: terminated.
02
Drugs
siremadlin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03940352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03940352.